ClinicalTrials.gg
RecruitingNCT07080242Updated Nov 12, 2026

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

A Phase 1 interventional study of BL-M14D1 in Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer and Metastatic Neuroendocrine Prostate Cancer, sponsored by SystImmune Inc.. Recruiting at 32 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by SystImmune Inc. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Nov 12, 2026First sites in Georgia and UkraineSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 73 studies in Carcinoma, Neuroendocrine with a site in United States — 19 open to participants now, 32 under way, 1 of them phase 3. Carcinoma, Neuroendocrine · United States.

Planned enrollment
23rd of 65
120 · median 60
Started
2025
with 4 others
Phase 1
16 of 73
7 open now
Primary completion
2027-12
later than 14 of 31 live
Registered
67th of 73
by date

Among the 73 studies in Carcinoma, Neuroendocrine with a site in United States, this one is the 23rd largest by planned enrollment of the 65 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 1, reaches primary completion later than 14 of the 31 other live ones, and was the 67th registered.

Carcinoma, Neuroendocrine

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 66 are open to participants now.

Browse Carcinoma, Neuroendocrine studies →

Open to participants now

19 of the 73 studies in Carcinoma, Neuroendocrine with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Carcinoma, Neuroendocrine studies recruiting now, 30 (64%) set no upper age limit and 10 (21%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Carcinoma, Neuroendocrine with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Read the detailed description

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

03

Conditions studied

  • Small Cell Lung Cancer Metastatic or Locally Advanced
  • Neuroendocrine Cancer
  • Metastatic Neuroendocrine Prostate Cancer
  • Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
  • Metastatic Advanced Merkel Cell Carcinoma
  • Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung
  • Locally Advanced Extrapulmonary Neuroendocrine Carcinoma
  • Locally Advanced Neuroendocrine Prostate Cancer
  • Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine
  • Locally Advanced Merkel Cell Carcinoma
  • Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented locally advanced or SCLC, large cell neuroendocrine cancer of the lung (LCNEC), neuroendocrine prostate cancer (NEPC), poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) or other extrapulmonary neuroendocrine carcinomas (EP-NECs), Merkel cell carcinoma (MCC), or other poorly differentiated and/or high-grade neuroendocrine neoplasms with evidence of DLL3 expression who have failed at least 1 line of standard therapy in the advanced/metastatic setting or are unable to receive standard treatment

    • Notes: For SCLC, the participant must have failed at least 1 line of platinum therapy in the advanced/metastatic setting.
    • No prior topoisomerase inhibitor-based ADC therapy is permitted.
  • In the dose expansion part, Cohort 6 (DLL3-Positive NEN Subgroup): participants will be eligible based on documented positive DLL3 expression.
  • At least one based on (Response Evaluation Criteria in Solid Tumors) v1.1
  • performance status (ECOG PS) of 0 to 1
  • Toxicity of previous antitumor therapy has returned to Grade ≤1 as defined by National Cancer Institute (NCI) v5.0, except for alopecia and endocrinopathies controlled by replacement therapy
  • No serious cardiac dysfunction and ≥50%
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Chemotherapy, biological therapy, immunotherapy, , targeted therapy (including small molecule inhibitor of tyrosine kinase), and other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration; radical radiotherapy, major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration; oral fluorouracil drugs such as tegafur, capecitabine, or palliative radiotherapy within 2 weeks prior to initial administration.
  • Participants who have received prior topoisomerase inhibitor-based ADC therapy
  • Participants with other prior or concurrent except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years
  • Participants with advanced/ lung diseases, such as poorly controlled (COPD) and asthma, restrictive lung disease, pulmonary hypertension etc.
  • Participants with primary neoplasms in the central nervous system (CNS), active or untreated , spinal cord compression, or carcinomatous meningitis should be excluded. Active brain metastases are defined as untreated symptomatic brain metastases or untreated brain metastases requiring systemic and/or anticonvulsants to control CNS-related symptoms. Patients with brain metastases are eligible if they meet any of the following criteria:

    1. untreated, asymptomatic brain metastases
    2. previously treated brain metastases may participate provided they are clinically stable with local therapy (eg, surgery or radiotherapy, currently asymptomatic, no longer requiring corticosteroid treatment, and recovered from all local therapy-related adverse events, as determined by the investigator
  • Participated in another clinical trial within 4 weeks prior to first dose of study treatment
  • Participants who are pregnant or breastfeeding, or planning to become pregnant during the study
  • Other conditions that the Investigator or Sponsor believes are not suitable for participating in this clinical trial
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Experimental BL-M14D1 administered Day 1 per cycle

    BL-M14D1 will be administered on Day 1 by intravenous (IV) infusion every 3 weeks

    Drug: BL-M14D1

Interventions

  • BL-M14D1 will be administered on D1 every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Assess safety and tolerability of BL-M14D1

    SAEs, AESIs, TEAEs, death, TEAEs leading to discontinuation, DLTs, physical examination findings (including ECOG PS), vital sign measurements, standard clinical laboratory parameters, ECG parameters (including the change-from-baseline ECG parameters), and ECHO/MUGA findings

    Time frame: 18 months

Secondary outcomes

  1. To characterize the PK of BL M14D1, total anti-DLL3 antibody, and payload (Ed-04)

    PK Endpoints: Serum concentration of BL-M14D1, total anti-DLL3 antibody, and free payload ED-04 vs time will be utilized, serum PK parameters will include Cmax, Tmax, AUC0-8, AUClast and, if possible, Kel, t1/2, CL, Vz, Vss of BL-M14D1, total anti-DLL-3 antibody, and Ed-04. These PK parameters will be calculated both after the first dose and after multiple doses if applicable.

    Time frame: 18 months

  2. To investigate the antitumor activity of BL-M14D1

    * Tumor response evaluated using RECIST v1.1, ORR, DCR, DoR, TTR, and PFS * OS

    Time frame: 18 months

07

Study locations

29 of 32 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 23, 2025
StartActual
Apr 28, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 1 site removed — first sites in Georgia and Ukraine. 7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • Clearview Cancer Institute · Huntsville, United StatesNot yet recruiting→Recruiting
  • UCLA · Los Angeles, United StatesNot yet recruiting→Recruiting
  • UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center) · San Francisco, United StatesNot yet recruiting→Recruiting
  • LLC "Caucasus Medical Centre" · Tbilisi, GeorgiaNot yet recruiting→Recruiting
  • LTD "High Technology Hospital Medcenter" · Batumi, GeorgiaNot yet recruiting→Recruiting
  • JSC "Vian" · Kutaisi, GeorgiaNot yet recruiting→Recruiting
  • LTD "New Hospitals" · Tbilisi, GeorgiaNot yet recruiting→Recruiting
Show 9 added (5 Georgia, 2 United States, 2 Ukraine)
  • OPN Healthcare · Glendale, United States
  • LTD "High Technology Hospital Medcenter" · Batumi, Georgia
  • JSC "Vian" · Kutaisi, Georgia
  • LTD "New Hospitals" · Tbilisi, Georgia
  • LTD "Pineo Medical Ecosystem" · Tbilisi, Georgia
  • LLC "Caucasus Medical Centre" · Tbilisi, Georgia
  • Regional Municipal Nonprofit Enterprise "Bukovinian clinical oncology center" of the Chernivtsi Regional Council · Chernivtsi, Ukraine
  • "The Municipal Enterprise "Volyn Regional Clinical Hospital" of the Volyn Regional Council, Regional Medical Oncology Centre" · Lutsk, Ukraine
  • Valkyrie Denver · Lakewood, United States
Show 1 removed
  • Los Alamitos Hematology/Oncology Medical Group · Glendale, United States
across 3 updates, Oct 28, 2026 – Nov 12, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • LTD "High Technology Hospital Medcenter" · Batumi, GeorgiaContact none listed→S•••@gmail.com · •••4770Contact added (no phone or email listed)
  • JSC "Vian" · Kutaisi, GeorgiaContact none listed→m•••@vian.health · •••5617Contact added (no phone or email listed)
  • LTD "New Hospitals" · Tbilisi, GeorgiaContact none listed→k•••@gmail.com · •••7997Contact added (no phone or email listed)
  • LTD "Pineo Medical Ecosystem" · Tbilisi, GeorgiaContact none listed→k•••@gmail.com · •••6376Contact added (no phone or email listed)
  • LLC "Caucasus Medical Centre" · Tbilisi, GeorgiaContact none listed→n•••@gmail.com · •••5375Contact added (no phone or email listed)
Oct 30, 2026
Show all 3 updates
  1. Nov 12, 2026
    1 site added. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • LTD "High Technology Hospital Medcenter" · Batumi, GeorgiaNot yet recruiting→Recruiting
    • JSC "Vian" · Kutaisi, GeorgiaNot yet recruiting→Recruiting
    • LTD "New Hospitals" · Tbilisi, GeorgiaNot yet recruiting→Recruiting
    Show site
    • Valkyrie Denver · Lakewood, United States
    + 1 other change: verification date
  2. Oct 30, 2026
    LLC "Caucasus Medical Centre" is now Recruiting
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • LTD "High Technology Hospital Medcenter" · Batumi, GeorgiaContact none listed→S•••@gmail.com · •••4770Contact added (no phone or email listed)
    • JSC "Vian" · Kutaisi, GeorgiaContact none listed→m•••@vian.health · •••5617Contact added (no phone or email listed)
    • LTD "New Hospitals" · Tbilisi, GeorgiaContact none listed→k•••@gmail.com · •••7997Contact added (no phone or email listed)
    • LTD "Pineo Medical Ecosystem" · Tbilisi, GeorgiaContact none listed→k•••@gmail.com · •••6376Contact added (no phone or email listed)
    • LLC "Caucasus Medical Centre" · Tbilisi, GeorgiaContact none listed→n•••@gmail.com · •••5375Contact added (no phone or email listed)
  3. Oct 28, 2026
    8 sites added, 1 site removed — first sites in Georgia and Ukraine. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Clearview Cancer Institute · Huntsville, United StatesNot yet recruiting→Recruiting
    • UCLA · Los Angeles, United StatesNot yet recruiting→Recruiting
    • UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center) · San Francisco, United StatesNot yet recruiting→Recruiting
    Show 8 added (5 Georgia, 2 Ukraine, 1 United States)
    • OPN Healthcare · Glendale, United States
    • LTD "High Technology Hospital Medcenter" · Batumi, Georgia
    • JSC "Vian" · Kutaisi, Georgia
    • LTD "New Hospitals" · Tbilisi, Georgia
    • LTD "Pineo Medical Ecosystem" · Tbilisi, Georgia
    • LLC "Caucasus Medical Centre" · Tbilisi, Georgia
    • Regional Municipal Nonprofit Enterprise "Bukovinian clinical oncology center" of the Chernivtsi Regional Council · Chernivtsi, Ukraine
    • "The Municipal Enterprise "Volyn Regional Clinical Hospital" of the Volyn Regional Council, Regional Medical Oncology Centre" · Lutsk, Ukraine
    Show 1 removed
    • Los Alamitos Hematology/Oncology Medical Group · Glendale, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07080242
Lead sponsor
SystImmune Inc.
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Apr 28, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Lien Huzzy
Contact
lien.huzzy@systimmune.com
4254536841
Whitney Eakins
Contact
whitney.eakins@systimmune.com
4254536841
Junliang Cai
study director · SystImmune Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-DLL3 Antibody-drug Conjugate BL-M14D1

Start the discussion